All Biomarkers

    Apolipoprotein B (ApoB)

    Metabolic
    Lipid Metabolism
    mg/dL

    Apolipoprotein B (ApoB) is a structural protein carried by every atherogenic lipoprotein — LDL, VLDL, IDL and Lp(a) — with exactly one ApoB-100 molecule per particle. Measuring ApoB therefore counts the total number of cholesterol-carrying particles capable of entering and damaging the arterial wall, making it the most direct blood measure of atherogenic particle burden. Two people with identical LDL-C can carry very different particle numbers, so ApoB frequently reclassifies cardiovascular risk that a standard lipid panel misses.

    What It Measures

    One ApoB molecule per atherogenic particle (LDL, VLDL, IDL, Lp(a)); best single marker of cardiovascular risk

    Optimal vs. Lab Range

    Longevity Optimal
    Risk-stratified (NLA 2024): <90 mg/dL intermediate risk; <70 mg/dL high risk; <60 mg/dL very-high risk

    Target range for optimal health and longevity based on research.

    Standard Lab
    <130 mg/dL (conventional 'high' threshold; population reference varies by lab)

    Population-based reference range from standard labs.

    Why It Matters

    Large Mendelian randomization and cohort analyses establish ApoB-containing particle number as a causal driver of atherosclerotic cardiovascular disease and arguably the single best lipid predictor of risk. The 2026 ACC/AHA Guideline on the Management of Dyslipidemia reaffirms a lifetime-exposure model — cardiovascular risk reflects both the concentration and the cumulative duration of exposure to ApoB-containing lipoproteins — and positions ApoB as a selective measure to identify residual risk once LDL-C and non-HDL-C goals are met, or when those measures are discordant (common with high triglycerides, insulin resistance and metabolic syndrome). The 2024 National Lipid Association Expert Clinical Consensus similarly concluded that ApoB (and non-HDL-C) stratify ASCVD risk more accurately than LDL-C. For a longevity-oriented practice, cumulative lifetime exposure to ApoB particles (not a single snapshot) shapes arterial aging, so measuring and lowering it early compounds benefit over decades.

    When Low

    Abetalipoproteinemia (extremely rare genetic condition)

    When Optimal

    Low atherogenic particle burden; each lower increment of ApoB is associated with proportionally lower atherosclerotic risk. Optimal targets are risk-stratified (see ranges).

    When High

    Atherosclerosis, myocardial infarction, stroke risk; each ApoB particle can enter arterial wall and initiate plaque

    How to Optimize

    ApoB tracks particle number, so strategies that lower atherogenic lipoproteins lower ApoB: reduced saturated and refined-carbohydrate intake, increased viscous fiber, weight and visceral-fat reduction, and regular aerobic plus resistance exercise. When lifestyle is insufficient for the individual's risk, evidence-based pharmacotherapy (statins, ezetimibe, bempedoic acid, PCSK9 inhibitors) markedly reduces ApoB. Retest 6–12 weeks after any change. Treatment intensity and targets are individualized with your physician; this content is educational and not a substitute for medical advice.

    Key Interventions & Linked Compounds

    Strong evidence

    Key Interventions

    Statin (clinical)
    PCSK9 inhibitor (clinical)
    ezetimibe
    bempedoic acid
    exercise
    low-carb diet

    Linked Compounds & Supplements

    Plant sterols
    Berberine
    Red yeast rice
    Omega-3
    Citrus bergamot

    Curated from clinical literature. Individual results vary; consult a qualified clinician before changing a protocol.

    Ordering Notes

    Specimen

    Serum or plasma (venous draw)

    Patient prep

    No fasting required. Maintain usual diet and medications unless advised.

    Recommended cadence

    Annual

    Reporting unit

    mg/dL

    Pre-analytic notes

    Standardize draw time of day, hydration, and recent exercise. Note any acute illness, supplements, or hormonal therapies on the requisition.

    Recommended Follow-Up Actions

    1. 1

      Confirm the result is reliable

      Repeat abnormal values before acting — preferably from the same lab, same time of day, and under consistent prep. Rule out acute illness, recent intense exercise, or medication effects that can shift Apolipoprotein B (ApoB).

    2. 2

      Compare against optimal, not just lab range

      Use the optimal window above as the target. Lab "normal" is built from the general population and often misses early dysfunction.

    3. 3

      Pair with related markers

      Order a complementary panel covering metabolic, inflammatory, and hormonal context to interpret this marker properly.

    4. 4

      Discuss interventions with a clinician

      Use the interpretation guidance above to frame the conversation. Bring trends, not just one datapoint, to your visit.

    5. 5

      Re-test on a defined cadence

      If a change is implemented, re-measure in 8–12 weeks for fast-moving markers, or 3–6 months for slower ones, to confirm response before escalating.

    Testing Information

    Recommended Frequency

    Annual

    Fasting Requirement

    No fasting required

    PHS
    671
    / 1000
    T3
    Longevity Operator

    Sample member

    Longevity Operator

    The Peak Human Score · PHS v1

    One number for your longevity journey.

    FICO for credit. PHS for longevity. Eight biological domains collapsed into one provable score — intuitive at a glance, rigorous underneath.

    • Metabolic
    • Hormonal
    • Cardiovascular
    • Brain / Cognitive
    • Sleep
    • Musculoskeletal
    • Gut
    • Immunity / Inflammation